Harry William Fischer, MD | |
17752 Chariot Rd, Elkader, IA 52043-8136 | |
(563) 245-3268 | |
Not Available |
Full Name | Harry William Fischer |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 17752 Chariot Rd, Elkader, Iowa |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1922182849 | NPI | - | NPPES |
105181 | Other | MO | LICENSE NUMBER |
234925601 | Other | MO | BNDD |
Mailing Address | Practice Location Address |
---|---|
Harry William Fischer, MD 17752 Chariot Rd, Elkader, IA 52043-8136 Ph: (563) 245-3268 | Harry William Fischer, MD 17752 Chariot Rd, Elkader, IA 52043-8136 Ph: (563) 245-3268 |
News Archive
"The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 45 new two-year grants, from 37 countries, totaling $419.2 million, to fund essential prevention, treatment, and care services provided to the people affected by the three diseases," according to a Global Fund press release.
Eastmont Community Center responded today to alarmingly low whooping cough and meningococcal meningitis immunization rates among Latino adolescents by launching a new adolescent immunization awareness initiative. The grassroots campaign aims to educate local Latino families about free or low-cost vaccines available to help protect children against these and other infectious diseases.
Both sides of the political aisle in Washington are continuing their Obamacare sparring sessions at home in their districts during the August recess with town hall meetings and debates on the law taking spotlight.
A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors. This dendritic cell (DC) vaccine, developed at Dartmouth and described in a research paper published this week in the journal Clinical Cancer Research, was used after surgical resection of metastatic tumors to try to prevent the growth of additional metastases.
Heart transplant patients who receive new organs before the age of 55 and get them at hospitals that perform at least nine heart transplants a year are significantly more likely than other people to survive at least 10 years after their operations, new Johns Hopkins research suggests.
› Verified 2 days ago